MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-08-31, TLRY had $43,162K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$43,162K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-08-31
2025-05-31
2025-02-28
2024-11-30
Asset impairment charges
-2,096,139 --
Other than temporary change in fair value of convertible notes receivable
-21,661 --
Litigation costs, net of recoveries
-17,347 --
Restructuring costs
-34,283 --
Change in fair value of contingent consideration
-0 --
Transaction costs (income), net
-4,534 --
Asset impairment charges
-1,396,904 699,235 -
Total operating expenses
-2,523,275 --
Other than temporary change in fair value of convertible notes receivable
-1,661 20,000 -
Operating loss
--2,282,705 --
Gross profit
-240,570 --
Interest expense, net
--29,952 --
Non-operating income (expense), net
-10,284 --
Loss before income taxes
--2,302,373 --
Income tax (recovery) expense
--121,017 --
Net (loss) income
1,513 -1,267,895 -793,534 -85,275
Deferred income tax (recovery) expense, net
-2,285 -123,703 1,157 1,147
Unrealized foreign exchange gain
2,328 48,943 -21,098 -15,229
Amortization
15,561 34,080 33,546 34,050
Loss (gain) on sale of capital assets
--928 --
Accretion of convertible debt discount
1,976 2,112 2,766 2,918
General and administrative
-167,324 --
Inventory valuation write down
-0 --
Unrealized loss on digital assets
-8 ---
Selling
-56,039 --
Other non-cash items
-282 3,706 1,778 -2,552
Amortization
-88,616 --
Stock-based compensation
5,052 6,100 4,035 7,237
Marketing and promotion
-37,048 --
Gain on long-term investments
39 -10 -5,474 -565
Research and development
-284 --
Loss (gain) on derivative instruments
-3,670 -735 1,338 862
Change in fair value of contingent consideration
-15,000 0 0 0
Accounts receivable
-14,414 18,122 -9,372 6,709
Prepaids and other current assets
7,133 6 -4,788 -524
Inventory
11,905 7,984 -2,550 -4,256
Accounts payable and accrued liabilities
-5,127 15,022 -13,132 -16,356
Net cash used in operating activities
-1,341 -12,807 -5,761 -40,724
Investment in capital and intangible assets
9,523 6,331 14,414 5,436
Proceeds from disposal of capital and intangible assets
293 5,991 202 603
Investment in digital assets
1,000 ---
Disposal (purchase) of marketable securities, net
-34,697 -13,761 -14,093 -12,318
Business acquisitions, net of cash acquired
--100 0 18,210
Net cash provided by (used in) investing activities
24,467 13,521 -119 -10,725
Share capital issued, net of cash issuance costs
22,491 21,450 28,221 45,045
Shares effectively repurchased for employee withholding tax
-0 --
Proceeds from long-term debt
-0 3,450 0
Repayment of long-term debt
2,653 -609 5,727 5,597
Proceeds from convertible debt
-0 0 0
Repayment of convertible debt
0 0 0 0
Repayment of lease liabilities
994 314 862 862
Net decrease in bank indebtedness
1,004 -3,559 -7,011 -383
Dividend paid to nci
-1,544 --
Net cash provided by financing activities
19,848 16,642 18,071 38,203
Effect of foreign exchange on cash and cash equivalents
188 4,354 -1,933 -2,242
Net increase (decrease) in cash and cash equivalents
43,162 21,710 10,258 -15,488
Cash and cash equivalents at beginning of period
221,666 199,956 189,698 205,186
Cash and cash equivalents at end of period
264,828 221,666 199,956 189,698
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tilray_MedMen_Presentation_August 17 2021-2-pdf-svg copy-svg

Tilray Brands, Inc. (TLRY)

Tilray_MedMen_Presentation_August 17 2021-2-pdf-svg copy-svg

Tilray Brands, Inc. (TLRY)